Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piers Blombery

Showing results (81-90 of 157) with videos related to

Pageof 16
Sort By:
British Journal of Haematology|October 10, 2025
Genomic variation in DDX41 identified through clinical sequencingCelestine Wells, Ing Soo Tiong, Sally Hunter, et al.
Ejhaem|April 28, 2025
Enhanced Disease Detection of Hairy Cell Leukaemia Through Next-Generation Sequencing Based <i>BRAF</i> <sup>V600E</sup> and Phased Variant AnalysisSimon Wu, Tamia Nguyen, Imogen Caldwell, et al.
Haematologica|August 21, 2020
Clonal independence of <i>JAK2</i> and <i>CALR</i> or <i>MPL</i> mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencingElla R Thompson, Tamia Nguyen, Yamuna Kankanige, et al.
Hemasphere|June 9, 2026
Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE studyChan Y Cheah, Piers Blombery, Amanda Johnston, et al.
Haematologica|May 21, 2016
Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphomaPiers Blombery, Ella R Thompson, Kate Jones, et al.
Hemasphere|December 31, 2025
Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemiaDanielle M Brander, Andrew W Roberts, Thomas J Kipps, et al.
Ejhaem|November 29, 2023
Persistence of <i>UBTF</i> tandem duplications in remission in acute myeloid leukaemiaSean Harrop, Phillip C Nguyen, David Byrne, et al.
Hemasphere|November 15, 2019
Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDSGareth P Gregory, Michael Dickinson, Costas K Yannakou, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 13, 2019
Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution seriesIsaac Goncalves, Kate Burbury, Michael Michael, et al.
Blood Advances|April 28, 2022
ALLSorts: an RNA-Seq subtype classifier for B-cell acute lymphoblastic leukemiaBreon Schmidt, Lauren M Brown, Georgina L Ryland, et al.
Pageof 16

Showing results (81-90 of 157) with videos related to

Sort By:
Pageof 16
British Journal of Haematology|October 10, 2025
Genomic variation in DDX41 identified through clinical sequencingCelestine Wells, Ing Soo Tiong, Sally Hunter, et al.
Ejhaem|April 28, 2025
Enhanced Disease Detection of Hairy Cell Leukaemia Through Next-Generation Sequencing Based <i>BRAF</i> <sup>V600E</sup> and Phased Variant AnalysisSimon Wu, Tamia Nguyen, Imogen Caldwell, et al.
Haematologica|August 21, 2020
Clonal independence of <i>JAK2</i> and <i>CALR</i> or <i>MPL</i> mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencingElla R Thompson, Tamia Nguyen, Yamuna Kankanige, et al.
Hemasphere|June 9, 2026
Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE studyChan Y Cheah, Piers Blombery, Amanda Johnston, et al.
Haematologica|May 21, 2016
Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphomaPiers Blombery, Ella R Thompson, Kate Jones, et al.
Hemasphere|December 31, 2025
Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemiaDanielle M Brander, Andrew W Roberts, Thomas J Kipps, et al.
Ejhaem|November 29, 2023
Persistence of <i>UBTF</i> tandem duplications in remission in acute myeloid leukaemiaSean Harrop, Phillip C Nguyen, David Byrne, et al.
Hemasphere|November 15, 2019
Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDSGareth P Gregory, Michael Dickinson, Costas K Yannakou, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 13, 2019
Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution seriesIsaac Goncalves, Kate Burbury, Michael Michael, et al.
Blood Advances|April 28, 2022
ALLSorts: an RNA-Seq subtype classifier for B-cell acute lymphoblastic leukemiaBreon Schmidt, Lauren M Brown, Georgina L Ryland, et al.
Pageof 16